Intelligent Bio Q3 revenue $1.06M (+46% YoY); cartridge sales up 59%

INTELLIGENT BIO SOLUTIONS INC.

2026-Q3 EPS reported -$7.54 revenue$3,069,373

Q3 cartridge revenue $703,538, up 59% YoY, representing 66% of total sales.
Gross profit margin expanded to 50.5% in Q3 (vs 46.8% prior year); nine-month margin 49.3%.
Nine-month revenue reached $3.07M, up 39% YoY; cash balance $6.86M at March 31, 2026.
Marketing spend in Q3 down 42% YoY while commercial momentum accelerated.
FDA 510(k) program advancing; new manufacturing partnership and Bouygues UK customer added.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.